hUCB Plasma Therapeutic for Neurodegenerative Diseases
Summary
The USPTO granted patent US12605409B1 to the University of South Florida covering a method of treating neurodegenerative diseases using plasma derived from human umbilical cord blood (hUCB plasma). The patent discloses that hUCB plasma attenuated hyperactive mitogen responses and reduced caspase 3/7 activity in ALS patient cells, supporting therapeutic efficacy. Assignee: University of South Florida; inventors: Svitlana Garbuzova-Davis, Jared Carl Ehrhart, and Paul R. Sanberg.
What changed
The USPTO issued patent US12605409B1 to the University of South Florida, covering a therapeutic method using human umbilical cord blood (hUCB) plasma for treating neurodegenerative disorders including ALS. The patent discloses that hUCB plasma modulated mitogen cell response and reduced caspase activity in ALS patient cells, suggesting efficacy both as a standalone therapeutic and as an additive to stem cell treatments.
Biotechnology and pharmaceutical companies developing cell-based or plasma therapies for neurodegenerative diseases should review this patent when assessing their IP landscape. The patent's broad claims covering hUCB plasma alone or in combination with stem cells may create market exclusivity considerations for competing therapeutic programs in this space.
Archived snapshot
Apr 21, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Plasma derived from human umbilical cord blood for the treatment of neurodegenerative disorders
Grant US12605409B1 Kind: B1 Apr 21, 2026
Assignee
University of South Florida
Inventors
Svitlana Garbuzova-Davis, Jared Carl Ehrhart, Paul R. Sanberg
Abstract
A method of treating neurodegenerative diseases using hUCB plasma is presented herein. hUCB plasma attenuated the hyperactive response (Group III) and potentiated the normal response in Group I ALS patients, but did not alter that of the non-responders to PHA (Group II). The elevated activity of caspase 3/7 observed in the MNCs from ALS patients was significantly reduced by hUCB plasma treatment. The ability of hUCB plasma to modulate the mitogen cell response and reduce caspase activity suggest that the use of hUCB plasma alone, or with stem cells, may prove useful as a therapeutic in ALS patients. hUCB plasma was shown to increase therapeutic efficacy of MNCs as well as decrease apoptosis of MNCs. The cytokine profile of hUCB plasma supports its usefulness as a sole therapeutic as well as an additive to MNCs.
CPC Classifications
A61K 35/51 C12N 5/0665 A61P 25/28
Filing Date
2023-04-14
Application No.
18134720
Claims
3
Mentioned entities
Parties
Related changes
Get daily alerts for USPTO Patent Grants - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.